Alembic Pharmaceuticals

• 

  Alembic Pharma Gets Regulator's Approval To Market Antidepressant Drug In US

  Alembic Pharmaceuticals has received an approval from the US Food & Drug Administration to market Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.

• 

  Alembic Receives USFDA Approval For Itraconazole Capsules

  Itraconazole capsules had an estimated market size of $42 million for twelve months ending December 2015.

• 

  Alembic Pharma Gets US Drug Regulator's Nod For Anti-Migraine Drug

  The tablets are indicated for acute treatment of migraine in adults.

• 

  Alembic Pharma Gets Tentative Nod From USFDA For Febuxostat

  Alembic Pharmaceuticals said it has settled the case with Takeda and will launch its generic as per the terms of settlement.

• 

  Alembic Pharma Says Plants Successfully Inspected By USFDA

  The company, however, did not provide any details about the observations it has received from the United States Food and Drug Administration.

• 

  Sun Pharma Bets On New Products To Boost US Skincare Products Growth

  India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said.

• 

  Alembic Pharma Posts 30% Rise In Q4 Profit

  Alembic Pharmaceuticals on Wednesday reported a 29.64 per cent rise in consolidated net profit at Rs 91.18 crore for the quarter ended March 2016.

• 

  Alembic Pharma Jumps Over 8% On Joint Venture With Orbicular Pharma

  Shares of Alembic Pharmaceuticals Ltd (APL) on Thursday surged over 8 per cent after the company entered into a joint venture with Orbicular Pharmaceutical to develop, manufacture and commercialise dermatology products for global markets.

• 

  Alembic Pharma Posts Four-Fold Rise in Q3 Profit

  Alembic Pharmaceuticals on Thursday reported a nearly 4-fold jump in consolidated net profit at Rs 269.49 crore for the quarter ended December 31, 2015, mainly on account of robust sales in the overseas market.

• 

  Alembic Pharma Arm Ties Up With Novartis for Drug Development

  As per the agreement, Switzerland-based Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sale milestones payments, it added.

• Alembic Pharma Q1 Net Up 8% to about Rs 70 Cr

  The company's India branded formulations business grew by 18 per cent to Rs 263 crore during the quarter as against Rs 223 crore for the same period year ago.

• Alembic Pharma Posts 14.7% Rise in Q4 Profit

  Vadodara-based drug firm Alembic Pharmaceuticals on Monday reported a 14.74 per cent increase in net profit at Rs 70.33 crore for the quarter ended March 31, 2015.

• Alembic Pharma Q2 Profit Up 25 Per Cent at Rs 77.27 Crore

  Alembic Pharmaceuticals on Monday reported a 25.35 per cent rise in consolidated net profit after tax and share of profit of associates to Rs 77.27 crore for the second quarter that ended on September 30, 2014-15, mainly on account of robust sales.

• UCB files cases against Ranbaxy, Aurobindo, Glenmark, others

  According to a petition filed by UCB Inc, UCB Pharma GMBH, Research Corporation Technologies, Inc and Harris FRC Corporation the patent of its drug Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg would expire on March 17, 2022.

• 

  Who is Chirayu Amin?

  Chirayu Amin is the CMD of Baroda-based Alembic Ltd, which is 100-year-old pharmaceutical firm with Rs 1200 crore turnover.